The Six-Patient Study Underneath an Interim Readout

Epidermolysis bullosa simplex is a genetic skin disorder caused by mutations in the keratin genes KRT5 or KRT14, and in its severe form it produces blistering wherever skin meets friction: hands, feet, torso, the soles most of all. No treatment for it has FDA approval. The Ohio biotech BioMendics is running a 40-patient trial, TAMES-02, testing a topical gel called TolaSure that the company says clears the aggregated, misfolded keratin inside skin cells rather than treating the blisters themselves.

The mechanism is specific enough to check. TolaSure's active compound, BM-3103, is described in company and investigator materials as a topical inhibitor of mTOR, a cell-growth pathway whose inhibition is already used elsewhere in medicine, in transplant immunosuppression and some cancer therapies, to switch on autophagy, the cell's internal cleanup process. In EBS keratinocytes, mutant keratin proteins misfold and clump instead of forming the filament network that gives skin its mechanical strength. BM-3103's proposed action is to push autophagy hard enough to clear those clumps and let a sturdier filament network reassemble, the same aggregate-clearing logic tried in neurodegenerative disease research, applied here to a structural protein in skin instead of the brain.

What the predecessor trial actually shows

TAMES-02's design leans on TAMES-01, a smaller pilot that investigators and BioMendics describe as having produced "rapid and substantial reductions in blister burden." That predecessor trial's own ClinicalTrials.gov record tells a narrower story than the confidence quoted around it. It was registered to enroll 10 adults with severe EBS. It completed, per the registry, with 6. It ran from May 2022 to June 2023, and its primary endpoint was not efficacy but the incidence of treatment-related adverse events, a safety measure. More than three years after it completed, the registry still lists no posted results; the only public record of what happened in those six patients is conference-abstract summaries and quotes from investigators and the company.

None of that means the drug does not work. A six-patient safety pilot is a normal, appropriately small first step, and companies are not always required to post results quickly. But it is a thin foundation for the language now circulating around TAMES-02, that the earlier trial's results were "rapid" and "substantial." Those are reported characterizations, not published data a reader can check directly.

TAMES-02 itself is a considerably more rigorous instrument: 40 participants aged 4 and up, randomized 1:1, placebo-controlled, with blister surface area as its primary endpoint and quality-of-life, pain, and itch measures alongside it. BioMendics has said it is nearing the roughly 20 patients needed for an interim look, with data possible by the end of the year. Whether that data confirms or complicates what TAMES-01 suggested is the real test, and it has not happened yet.

Sources: ClinicalTrials.gov (TAMES-02, NCT07027345) · ClinicalTrials.gov (TAMES-01, NCT05062070) · BioMendics FDA Fast Track announcement